DXCM
DexCom, Inc. NASDAQ Listed Apr 14, 2005$60.93
Mkt Cap $23.5B
52w Low $54.11
19.0% of range
52w High $89.98
50d MA $65.06
200d MA $69.13
P/E (TTM)
28.7x
EV/EBITDA
22.7x
P/B
8.7x
Debt/Equity
0.5x
ROE
30.5%
P/FCF
24.0x
RSI (14)
—
ATR (14)
—
Beta
1.56
50d MA
$65.06
200d MA
$69.13
Avg Volume
4.5M
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
6340 Sequence Drive · San Diego, CA 92121 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | AMC | 0.47 | 0.56 | +19.1% | 59.55 | +2.4% | +3.0% | -2.1% | -0.9% | +1.5% | +0.9% | — |
| Feb 12, 2026 | AMC | 0.65 | 0.68 | +4.6% | 65.08 | -1.0% | +7.6% | +0.6% | +3.4% | -0.7% | +1.1% | — |
| Oct 30, 2025 | AMC | 0.58 | 0.61 | +5.9% | 68.20 | -13.2% | -14.6% | +3.8% | +1.2% | -3.1% | -2.1% | — |
| Jul 30, 2025 | AMC | 0.44 | 0.48 | +8.2% | 89.06 | -3.8% | -9.3% | -1.8% | -3.8% | -1.0% | +1.2% | — |
| May 1, 2025 | AMC | 0.33 | 0.32 | -2.2% | 70.26 | +7.1% | +16.2% | -1.7% | +1.6% | +2.2% | +2.4% | — |
| Feb 13, 2025 | AMC | 0.48 | 0.45 | -6.1% | 84.09 | +2.3% | +5.9% | +1.6% | -0.9% | -0.4% | -0.6% | — |
| Oct 24, 2024 | AMC | 0.44 | 0.45 | +2.3% | 74.85 | -1.9% | -1.9% | -1.8% | +0.2% | -0.6% | -1.8% | — |
| Jul 25, 2024 | AMC | 0.39 | 0.43 | +10.3% | 107.85 | -38.8% | -40.7% | +5.4% | +3.3% | -2.7% | +3.7% | — |
| Apr 25, 2024 | AMC | 0.27 | 0.32 | +18.5% | 138.01 | -4.0% | -9.9% | +1.2% | +1.3% | -1.2% | +0.6% | — |
| Feb 8, 2024 | AMC | 0.43 | 0.50 | +16.3% | 127.05 | -3.2% | -5.2% | -1.7% | -1.2% | -0.2% | +0.8% | — |
| Oct 26, 2023 | AMC | 0.34 | 0.50 | +47.1% | 81.09 | +14.4% | +10.1% | -4.9% | +4.6% | +6.0% | -0.5% | — |
| Jul 27, 2023 | AMC | 0.23 | 0.34 | +47.8% | 129.36 | +3.9% | +2.3% | -5.9% | -2.1% | +1.5% | -1.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1 | Canaccord Genuity | Maintains | Buy → Buy | — | $59.55 | $60.99 | +2.4% | +3.0% | -2.1% | -0.9% | +1.5% | +0.9% |
| May 1 | TD Cowen | Maintains | Buy → Buy | — | $59.55 | $60.99 | +2.4% | +3.0% | -2.1% | -0.9% | +1.5% | +0.9% |
| May 1 | Barclays | Maintains | Underweight → Underweight | — | $59.55 | $60.99 | +2.4% | +3.0% | -2.1% | -0.9% | +1.5% | +0.9% |
| Mar 11 | Citigroup | Maintains | Buy → Buy | — | $67.79 | $67.11 | -1.0% | -2.2% | -1.6% | -1.6% | +3.3% | +1.5% |
| Mar 9 | BTIG | Maintains | Buy → Buy | — | $68.10 | $67.02 | -1.6% | +0.9% | -1.4% | -2.2% | -1.6% | -1.6% |
| Feb 25 | BTIG | Maintains | Buy → Buy | — | $73.09 | $73.42 | +0.5% | +0.1% | +1.7% | -1.3% | +0.5% | -0.9% |
| Feb 17 | Truist | Maintains | Buy → Buy | — | $70.02 | $70.25 | +0.3% | +0.6% | +3.4% | -0.7% | +1.1% | +0.2% |
| Feb 13 | BTIG | Maintains | Buy → Buy | — | $65.08 | $64.44 | -1.0% | +7.6% | +0.6% | +3.4% | -0.7% | +1.1% |
| Feb 13 | Mizuho | Maintains | Outperform → Outperform | — | $65.08 | $64.44 | -1.0% | +7.6% | +0.6% | +3.4% | -0.7% | +1.1% |
| Feb 13 | Wells Fargo | Maintains | Overweight → Overweight | — | $65.08 | $64.44 | -1.0% | +7.6% | +0.6% | +3.4% | -0.7% | +1.1% |
| Feb 13 | Barclays | Maintains | Underweight → Underweight | — | $65.08 | $64.44 | -1.0% | +7.6% | +0.6% | +3.4% | -0.7% | +1.1% |
| Feb 13 | Canaccord Genuity | Maintains | Buy → Buy | — | $65.08 | $64.44 | -1.0% | +7.6% | +0.6% | +3.4% | -0.7% | +1.1% |
| Jan 12 | Barclays | Downgrade | Equal Weight → Underweight | — | $67.40 | $66.74 | -1.0% | +5.3% | -1.0% | -0.8% | -0.7% | +0.4% |
| Jan 9 | Bernstein | Maintains | Outperform → Outperform | — | $68.43 | $68.61 | +0.3% | -1.5% | +5.3% | -1.0% | -0.8% | -0.7% |
| Dec 17 | Mizuho | Maintains | Outperform → Outperform | — | $66.37 | $66.18 | -0.3% | -0.9% | +0.2% | +0.2% | +2.1% | -0.8% |
| Dec 11 | Citigroup | Maintains | Buy → Buy | — | $67.56 | $67.98 | +0.6% | +2.0% | -2.9% | -1.8% | +1.0% | -0.9% |
| Dec 2 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | $63.52 | $65.09 | +2.5% | +1.5% | +0.6% | +0.6% | +0.4% | +0.2% |
| Nov 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $55.00 | $55.16 | +0.3% | -0.3% | +6.0% | +2.5% | +0.2% | -2.8% |
| Nov 7 | Argus | Maintains | Buy → Buy | — | $58.02 | $58.02 | +0.0% | -5.2% | -0.3% | +6.0% | +2.5% | +0.2% |
| Nov 3 | UBS | Maintains | Buy → Buy | — | $58.22 | $58.55 | +0.6% | +3.8% | +1.2% | -3.1% | -2.1% | -5.2% |
| Nov 3 | Truist | Maintains | Buy → Buy | — | $58.22 | $58.55 | +0.6% | +3.8% | +1.2% | -3.1% | -2.1% | -5.2% |
| Nov 3 | Barclays | Maintains | Equal Weight → Equal Weight | — | $58.22 | $58.55 | +0.6% | +3.8% | +1.2% | -3.1% | -2.1% | -5.2% |
| Oct 31 | Wells Fargo | Maintains | Overweight → Overweight | — | $68.20 | $59.19 | -13.2% | -14.6% | +3.8% | +1.2% | -3.1% | -2.1% |
| Oct 31 | RBC Capital | Maintains | Outperform → Outperform | — | $68.20 | $59.19 | -13.2% | -14.6% | +3.8% | +1.2% | -3.1% | -2.1% |
| Oct 31 | TD Cowen | Maintains | Buy → Buy | — | $68.20 | $59.19 | -13.2% | -14.6% | +3.8% | +1.2% | -3.1% | -2.1% |
| Oct 31 | Piper Sandler | Maintains | Overweight → Overweight | — | $68.20 | $59.19 | -13.2% | -14.6% | +3.8% | +1.2% | -3.1% | -2.1% |
| Oct 31 | Canaccord Genuity | Maintains | Buy → Buy | — | $68.20 | $59.19 | -13.2% | -14.6% | +3.8% | +1.2% | -3.1% | -2.1% |
| Oct 31 | Citigroup | Maintains | Buy → Buy | — | $68.20 | $59.19 | -13.2% | -14.6% | +3.8% | +1.2% | -3.1% | -2.1% |
| Oct 31 | JP Morgan | Maintains | Neutral → Neutral | — | $68.20 | $59.19 | -13.2% | -14.6% | +3.8% | +1.2% | -3.1% | -2.1% |
| Oct 31 | BTIG | Maintains | Buy → Buy | — | $68.20 | $59.19 | -13.2% | -14.6% | +3.8% | +1.2% | -3.1% | -2.1% |
| Oct 15 | Truist | Maintains | Buy → Buy | — | $66.21 | $66.35 | +0.2% | -1.2% | +1.4% | +0.4% | +2.7% | +1.9% |
| Oct 7 | Citigroup | Maintains | Buy → Buy | — | $66.36 | $66.77 | +0.6% | -0.5% | +2.7% | +0.4% | -4.3% | +0.1% |
| Oct 1 | Goldman Sachs | Maintains | Buy → Buy | — | $67.29 | $67.21 | -0.1% | -1.8% | +0.5% | +0.9% | -1.0% | -0.5% |
| Sep 29 | Canaccord Genuity | Maintains | Buy → Buy | — | $67.10 | $67.34 | +0.4% | -1.0% | +1.2% | -1.8% | +0.5% | +0.9% |
| Sep 26 | Baird | Maintains | Outperform → Outperform | — | $68.30 | $68.05 | -0.4% | -1.8% | -1.0% | +1.2% | -1.8% | +0.5% |
| Aug 1 | Canaccord Genuity | Maintains | Buy → Buy | — | $80.77 | $80.57 | -0.2% | -1.8% | -3.8% | -1.0% | +1.2% | +0.0% |
| Jul 31 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $89.06 | $85.70 | -3.8% | -9.3% | -1.8% | -3.8% | -1.0% | +1.2% |
| Jul 31 | Piper Sandler | Maintains | Overweight → Overweight | — | $89.06 | $85.70 | -3.8% | -9.3% | -1.8% | -3.8% | -1.0% | +1.2% |
| Jul 31 | UBS | Maintains | Buy → Buy | — | $89.06 | $85.70 | -3.8% | -9.3% | -1.8% | -3.8% | -1.0% | +1.2% |
| Jul 31 | Oppenheimer | Maintains | Outperform → Outperform | — | $89.06 | $85.70 | -3.8% | -9.3% | -1.8% | -3.8% | -1.0% | +1.2% |
| Jul 30 | Barclays | Maintains | Equal Weight → Equal Weight | — | $89.35 | $89.35 | +0.0% | -0.3% | -9.3% | -1.8% | -3.8% | -1.0% |
| Jul 16 | Mizuho | Maintains | Outperform → Outperform | — | $84.78 | $85.49 | +0.8% | -0.8% | -0.0% | -0.2% | +0.2% | +1.3% |
| Jul 15 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $85.33 | $86.03 | +0.8% | -0.6% | -0.8% | -0.0% | -0.2% | +0.2% |
| May 22 | Citigroup | Maintains | Buy → Buy | — | $84.89 | $84.90 | +0.0% | -0.1% | -0.4% | +1.0% | +1.9% | -2.4% |
| May 5 | Barclays | Maintains | Equal Weight → Equal Weight | — | $81.62 | $81.65 | +0.0% | -1.7% | +1.6% | +2.2% | +2.4% | -0.8% |
| May 2 | Canaccord Genuity | Maintains | Buy → Buy | — | $70.26 | $75.26 | +7.1% | +16.2% | -1.7% | +1.6% | +2.2% | +2.4% |
| May 2 | Piper Sandler | Maintains | Overweight → Overweight | — | $70.26 | $75.26 | +7.1% | +16.2% | -1.7% | +1.6% | +2.2% | +2.4% |
| May 2 | Baird | Maintains | Outperform → Outperform | — | $70.26 | $75.26 | +7.1% | +16.2% | -1.7% | +1.6% | +2.2% | +2.4% |
| Mar 4 | Citigroup | Maintains | Buy → Buy | — | $85.99 | $85.76 | -0.3% | -4.2% | -0.6% | -3.0% | -2.1% | -9.1% |
| Feb 14 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $84.09 | $86.03 | +2.3% | +5.9% | +1.6% | -0.9% | -0.4% | -0.6% |
No insider trades available.
8-K · 5.02
!!! Very High
DexCom, Inc. -- 8-K 5.02: Executive Change
DexCom appoints Sayer as Executive Chairman starting January 1, 2026, signaling potential strategic shifts in leadership and company direction for investors to monitor.
Mar 2
8-K · 5.02
!!! Very High
DexCom, Inc. -- 8-K 5.02: Executive Change
DexCom appointed Albert F and Mr. Osterloh as directors, expanding board oversight of the continuous glucose monitoring company's operations and strategic direction.
Feb 26
8-K
DexCom, Inc. -- 8-K Filing
DexCom reported strong fourth-quarter 2025 revenue growth of 13% year-over-year to $1.260 billion, demonstrating continued market expansion for its continuous glucose monitoring devices despite competitive pressures.
Feb 12
Data updated apr 25, 2026 6:07am
· Source: massive.com